

The following **Listing of the Claims** will replace all prior versions and all prior listings of the claims in the present application:

**Listing of the Claims:**

1. (Canceled)
2. (Canceled)
3. (Currently Amended) A method of treating diabetes and/or microvascular diabetic complications comprising administering C-peptide or a pharmaceutical composition comprising C-peptide to a patient once daily, wherein said once daily administration does not include a continuous administration or the presence of release rate-controlling agents, and wherein said administration is by subcutaneous administration.
4. (Canceled)
5. (Canceled)
6. (Canceled)
7. (Canceled)
8. (Canceled)
9. (Canceled)
10. (Previously Amended) The method according to claim 3, wherein said C-peptide is human C-peptide
11. (Previously Presented) The method according to claim 3, wherein said C-peptide is a fragment EGSLQ (SEQ ID NO: 2).
12. (Previously Amended) The method according to claim 3, wherein said patient is a human.
13. (Previously Amended) The method according to claim 3, wherein said pharmaceutical composition contains 100 to 1800 nmol of C-peptide.
14. (Previously Amended) The method according to claim 3, wherein said C-peptide is in an aqueous solution.
15. (Currently Amended) The method according to claim 3, wherein said complications are diabetic nephropathy, retinopathy or neuropathy.